Why Design Therapeutics, Inc.’s (DSGN) Stock Is Down 6.21%
As of Thursday, July 16, Design Therapeutics, Inc.’s DSGN share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Commentary & Analysis
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.40%
As of Monday, July 13, Design Therapeutics, Inc.’s DSGN share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Up 5.06%
As of Tuesday, June 30, Design Therapeutics, Inc.’s DSGN share price has surged by 5.06%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Up 5.42%
As of Wednesday, June 24, Design Therapeutics, Inc.’s DSGN share price has surged by 5.42%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Up 5.06%
As of Monday, June 22, Design Therapeutics, Inc.’s DSGN share price has surged by 5.06%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $971.9 | $288.9 | 45% |
|
| Shares Out (Mil) | 62.5 | 54.0 | 53% |
|
| Institutional Ownership | 82.8% | 93.1% | 51% |
|
| Float (Mil) | 36.2 | 41.4 | 40% |
|
| Beta | 1.64 | 0.94 | 86% |
|
| Avg Daily Volume (000s) | 619 | 480 | 63% |
|
| Price Change (52-week) |
171.0% | 59.9% | 96% |
|
| Growth | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (53.1%) | (10.1%) | 6% |
|
| EPS (5yr) | (18.4%) | 15.9% | 15 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (21.7%) | (15.6%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.353) | ($1.363) | ($1.593) | |
| Month Ago EPS | ($0.359) | ($1.360) | ($1.636) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.359) | ($1.360) | ($1.636) | |
| Year/Year Chg | 9.3% | 12.0% | 63.2% | |
| Financials | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($71) | ($43) | 13% |
|
| EPS (TTM) | ($1.182) | ($1.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($55) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $594 | $190 | 35% |
|
| Valuation | DSGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.81 | 2.84 | 77% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | DSGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (32.3%) | (47.7%) | 16% |
|
| ROE | (34.1%) | (55.0%) | 19% |
|
| Liabilities to Assets | 6.2% | 29.6% | 3% |
|
| F-Score | 1 | 3 | 1% |
|
Design Therapeutics, Inc. did not pass any screens on 9/2/2026.
